BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Gemcitabine: trial readouts and FDA decisions

16 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 17 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Gilead Sciences, Sichuan Baili Pharmaceutical Co., Ltd., BeyondBio Inc., SynerGene Therapeutics, Inc., Karyopharm Therapeutics Inc, GC Cell Corporation, Janssen Research & Development, LLC, SynerGene Therapeutics, Inc., Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Akeso, RemeGen Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., CStone Pharmaceuticals, Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC, Grit Biotechnology, ImmunityBio, Inc., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Astellas Pharma Global Development, Inc., Verastem, Inc., TJ Biopharma Co., Ltd., Panbela Therapeutics, Inc., Genmab, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Boehringer Ingelheim, Prestige Biopharma Limited, Qilu Pharmaceutical Co., Ltd., Revolution Medicines, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2BeyondBio Inc.NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic CancerLocally Advanced or Metastatic Pancreatic Cancerrecruiting75
2026-12 est.P2SynerGene Therapeutics, Inc.NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic CancerMetastatic Pancreatic Canceractive not recruiting28
2026-12 est.P2/P3Karyopharm Therapeutics Inc KPTIQNCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphomaactive not recruiting501
2026-12 est.P3Gilead Sciences GILDNCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Metastatic Breast Canceractive not recruiting331
2026-12 est.P3GC Cell CorporationNCT04969731 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic CancerPancreatic Ductal Adenocarcinomarecruiting408
2026-12-30 est.P3Janssen Research & Development, LLCNCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderUrinary Bladder Neoplasmsactive not recruiting518
2026-12-30 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerBiliary Tract Canceractive not recruiting93
2026-12-31 est.P1/P2AkesoNCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsAdvanced Malignant Tumorsactive not recruiting154
2026-12-31 est.P3RemeGen Co., Ltd.NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaUrothelial Carcinoma; HER2-expressingrecruiting452
2026-12-31 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast Cancerrecruiting376
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-29 est.P3Seagen, a wholly owned subsidiary of PfizerNCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Urothelial Carcinomaactive not recruiting412
2027-01-31 est.P3Merck Sharp & Dohme LLC MRKNCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99Urinary Bladder Neoplasmsactive not recruiting520
2027-01-31 est.P2Grit BiotechnologyNCT06241781 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2027-02 est.P3Gilead Sciences GILDNCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally AdTriple Negative Breast Cancer; PD-L1 Positiveactive not recruiting443
2026-12-30 est.P1/P2AkesoNCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic CancerMetastatic Pancreatic Ductal Adenocarcinomaactive not recruiting110

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-17 est.P2AstraZeneca AZNNCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcirecruiting226
2026-11 est.P2ImmunityBio, Inc. IBRXNCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)not yet recruiting20
2026-11 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsPancreatic Neoplasmsrecruiting80
2026-11 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Nasopharyngeal Carcinomaactive not recruiting386
2026-10-31 est.P2Astellas Pharma Global Development, Inc.NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerPancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinomaactive not recruiting393
2026-10-27 est.P2AstraZeneca AZNNCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerHepatocellular Carcinoma; Biliary Tract Canceractive not recruiting294
2026-08-31 est.P1/P2Verastem, Inc. VSTMNCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerKRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplaactive not recruiting40
2026-08-30 est.P2TJ Biopharma Co., Ltd.NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated LocaNon Small Cell Lung Canceractive not recruiting150
2026-08-29 est.P2/P3Panbela Therapeutics, Inc.NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerPancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IVrecruiting600
2026-08-18P3Genmab GMABNCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPlatinum-resistant Ovarian Canceractive not recruiting584
2026-08-18 est.P3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerTriple Negative Breast Canceractive not recruiting350
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast CancHR+HER2- Breast Canceractive not recruiting383
2026-07-03 est.P3Boehringer IngelheimNCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS)withdrawn
2026-07 est.P1/P2Prestige Biopharma Limited PBHNCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic CancerPancreatic Canceractive not recruiting80
2026-06-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid Tumornot yet recruiting360
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.